DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 1m ago
GENS.F logo

Genus plcOTCPK:GENS.F Stock Report

Market Cap US$2.1b
Updated 1m ago
Share Price
n/a
1Y-6.7%
7D0%
1D0.3%
Portfolio Value
​
View

Genus plc

OTCPK:GENS.F Stock Report

Market Cap: US$2.1b

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Genus (GENS.F) Stock Overview

Produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. More details

GENS.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends5/6

Rewards

Became profitable this year

Pays a reliable dividend of 1.39%

Risk Analysis

Earnings are forecast to decline by an average of 10.7% per year for the next 3 years

Shares are highly illiquid

Large one-off items impacting financial results


GENS.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,300 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
440,300 investors already sharing narratives
US$
Current Price
US$31.0737.6% overvalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-7m732m2016201920222025202620282031Revenue UK£732.5mEarnings UK£51.8m
Advanced
View all narratives

Genus plc Competitors

Hyperliquid Strategies

Symbol: NasdaqCM:PURR
Market cap: US$2.3b

Vor Biopharma

Symbol: NasdaqGS:VOR
Market cap: US$1.3b

Vericel

Symbol: NasdaqGM:VCEL
Market cap: US$2.0b

CareDx

Symbol: NasdaqGM:CDNA
Market cap: US$2.6b

Price History & Performance

Summary of share price highs, lows and changes for Genus
Historical stock prices
Current Share PriceUK£31.07
52 Week HighUK£37.25
52 Week LowUK£30.98
Beta0.90
1 Month Change0%
3 Month Change-1.38%
1 Year Change-6.68%
3 Year Changen/a
5 Year Change-57.45%
Change since IPO103.31%

Recent News & Updates

Recent updates

Shareholder Returns

GENS.FUS BiotechsUS Market
7D0%-5.3%-1.0%
1Y-6.7%37.0%14.1%

Return vs Industry: GENS.F underperformed the US Biotechs industry which returned 40.9% over the past year.

Return vs Market: GENS.F underperformed the US Market which returned 20.6% over the past year.

Price Volatility

Is GENS.F's price volatile compared to industry and market?
GENS.F volatility
GENS.F Average Weekly Movementn/a
Biotechs Industry Average Movement9.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: GENS.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine GENS.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19943,190JK Kokkewww.genusplc.com

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand.

Genus plc Fundamentals Summary

How do Genus's earnings and revenue compare to its market cap?
GENS.F fundamental statistics
Market capUS$2.08b
Earnings (TTM)US$64.11m
Revenue (TTM)US$907.05m
32.5x
P/E Ratio
2.3x
P/S Ratio

Is GENS.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GENS.F income statement (TTM)
RevenueUK£672.00m
Cost of RevenueUK£402.40m
Gross ProfitUK£269.60m
Other ExpensesUK£222.10m
EarningsUK£47.50m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Sep 10, 2026

Earnings per share (EPS)0.71
Gross Margin40.12%
Net Profit Margin7.07%
Debt/Equity Ratio46.4%

How did GENS.F perform over the long term?

See historical performance and comparison

Dividends

1.4%
Current Dividend Yield
46%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/09 01:01
End of Day Share Price 2026/05/13 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genus plc is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Adam TomlinsonBerenberg
Matthew LloydBNP Paribas
Matthew John YatesBofA Global Research

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide